Strategies for MMP inhibition in cancer: innovations for the post-trial era
- PMID: 12209155
- DOI: 10.1038/nrc884
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Abstract
For more than two decades, the view that tumour-associated matrix metalloproteinases (MMPs) were required for peritumour tissue degradation and metastasis dominated the drive to develop MMP inhibitors as anticancer therapeutics. Until recently, clinical trials with MMP inhibitors have yielded disappointing results, highlighting the need for better insight into the mechanisms by which this growing family of multifunctional enzymes contribute to tumour growth. It is now recognized that MMP activity is tightly regulated at several levels, providing new avenues for blocking these enzymes. What are the different approaches that can be used to target MMPs, and which of these might lead to new therapeutic strategies for cancer?
Similar articles
-
Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.Int J Dev Biol. 2004;48(5-6):411-24. doi: 10.1387/ijdb.041811af. Int J Dev Biol. 2004. PMID: 15349816 Review.
-
Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach.Expert Rev Anticancer Ther. 2005 Feb;5(1):149-63. doi: 10.1586/14737140.5.1.149. Expert Rev Anticancer Ther. 2005. PMID: 15757447 Review.
-
Biological activity and clinical implications of the matrix metalloproteinases.Anticancer Res. 2008 Mar-Apr;28(2B):1389-97. Anticancer Res. 2008. PMID: 18505085 Review.
-
Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP). A new function for an "old friend".Biochimie. 2005 Mar-Apr;87(3-4):369-76. doi: 10.1016/j.biochi.2004.11.013. Biochimie. 2005. PMID: 15781324 Review.
-
The biological role and regulation of matrix metalloproteinases (MMP) in cancer.Arkh Patol. 2002 May-Jun;64(3):47-53. Arkh Patol. 2002. PMID: 15338725 Review.
Cited by
-
Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer.Cancer Biol Ther. 2024 Dec 31;25(1):2392341. doi: 10.1080/15384047.2024.2392341. Epub 2024 Aug 20. Cancer Biol Ther. 2024. PMID: 39164192 Free PMC article. Review.
-
Natural Compounds as Protease Inhibitors in Therapeutic Focus on Cancer Therapy.Anticancer Agents Med Chem. 2024;24(16):1167-1181. doi: 10.2174/0118715206303964240708095110. Anticancer Agents Med Chem. 2024. PMID: 38988167 Review.
-
Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.Front Pharmacol. 2024 May 7;15:1384731. doi: 10.3389/fphar.2024.1384731. eCollection 2024. Front Pharmacol. 2024. PMID: 38774209 Free PMC article.
-
CD10 Expression Correlates with Earlier Tumour Stages and Left-Sided Tumour Location in Colorectal Cancer but Has No Prognostic Impact in a European Cohort.Cancers (Basel). 2024 Apr 11;16(8):1473. doi: 10.3390/cancers16081473. Cancers (Basel). 2024. PMID: 38672555 Free PMC article.
-
Anithiactin D, a Phenylthiazole Natural Product from Mudflat-Derived Streptomyces sp., Suppresses Motility of Cancer Cells.Mar Drugs. 2024 Feb 14;22(2):88. doi: 10.3390/md22020088. Mar Drugs. 2024. PMID: 38393059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources